TransCode Therapeutics, Inc. – NASDAQ:RNAZ
TransCode Therapeutics stock price today
TransCode Therapeutics stock price monthly change
TransCode Therapeutics stock price quarterly change
TransCode Therapeutics stock price yearly change
TransCode Therapeutics key metrics
Market Cap | 2.51M |
Enterprise value | N/A |
P/E | -0.34 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 0.72 |
PEG ratio | N/A |
EPS | -227.11 |
Revenue | N/A |
EBITDA | -16.61M |
Income | -17.05M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTransCode Therapeutics stock price history
TransCode Therapeutics stock forecast
TransCode Therapeutics financial statements
| Jun 2023 | 0 | -4.34M | |
|---|---|---|---|
| Sep 2023 | 0 | -5.29M | |
| Dec 2023 | 753.14K | -4.08M | -542.73% |
| Mar 2024 | 0 | -3.32M |
| 2025 | 0 | -119.93K | |
|---|---|---|---|
| 2026 | 0 | -84.13K | |
| 2027 | 9.7M | -82.34K | -0.85% |
| 2028 | 9.9M | -69.81K | -0.71% |
Analysts Price target
Financials & Ratios estimates
| 2023-08-14 | -135.6 | -131.6 |
|---|---|---|
| 2023-11-13 | -1.09 | -1.68 |
| Jun 2023 | 5881545 | 3.78M | 64.42% |
|---|---|---|---|
| Sep 2023 | 10227846 | 5.78M | 56.59% |
| Dec 2023 | 5169701 | 3.52M | 68.26% |
| Mar 2024 | 7290467 | 2.70M | 37.12% |
| Jun 2023 | -4.39M | -18.10K | 6.35M |
|---|---|---|---|
| Sep 2023 | -3.50M | -4.60K | 7.39M |
| Dec 2023 | -5.66M | -35.57M | 978.15K |
| Mar 2024 | -3.93M | -3.83K | 6.08M |
TransCode Therapeutics alternative data
| Aug 2023 | 19 |
|---|---|
| Sep 2023 | 19 |
| Oct 2023 | 19 |
| Nov 2023 | 19 |
| Dec 2023 | 19 |
| Jan 2024 | 19 |
| Feb 2024 | 19 |
| Mar 2024 | 19 |
| Apr 2024 | 19 |
| May 2024 | 10 |
| Jun 2024 | 10 |
| Jul 2024 | 10 |
TransCode Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Jun 2023 | 56607 | 0 |
| Sep 2023 | 147350 | 0 |
| Quarter | Transcript |
|---|---|
| Q4 2021 7 Apr 2022 | Q4 2021 Earnings Call Transcript |
-
What's the price of TransCode Therapeutics stock today?
One share of TransCode Therapeutics stock can currently be purchased for approximately $9.96.
-
When is TransCode Therapeutics's next earnings date?
Unfortunately, TransCode Therapeutics's (RNAZ) next earnings date is currently unknown.
-
Does TransCode Therapeutics pay dividends?
No, TransCode Therapeutics does not pay dividends.
-
How much money does TransCode Therapeutics make?
TransCode Therapeutics has a market capitalization of 2.51M. TransCode Therapeutics made a loss 18.55M US dollars in net income (profit) last year or -$1.68 on an earnings per share basis.
-
What is TransCode Therapeutics's stock symbol?
TransCode Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "RNAZ".
-
What is TransCode Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of TransCode Therapeutics?
Shares of TransCode Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does TransCode Therapeutics have?
As Jul 2024, TransCode Therapeutics employs 10 workers, which is 47% less then previous quarter.
-
When TransCode Therapeutics went public?
TransCode Therapeutics, Inc. is publicly traded company for more then 4 years since IPO on 8 Jul 2021.
-
What is TransCode Therapeutics's official website?
The official website for TransCode Therapeutics is transcodetherapeutics.com.
-
Where are TransCode Therapeutics's headquarters?
TransCode Therapeutics is headquartered at 6 Liberty Square, Boston, MA.
-
How can i contact TransCode Therapeutics?
TransCode Therapeutics's mailing address is 6 Liberty Square, Boston, MA and company can be reached via phone at 857-837-3099.
TransCode Therapeutics company profile:
TransCode Therapeutics, Inc.
transcodetherapeutics.comNASDAQ
10
Biotechnology
Healthcare
TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Boston, MA 02109
CIK: 0001829635
ISIN: US89357L3033
CUSIP: 89357L105
